JP2013508382A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013508382A5 JP2013508382A5 JP2012535319A JP2012535319A JP2013508382A5 JP 2013508382 A5 JP2013508382 A5 JP 2013508382A5 JP 2012535319 A JP2012535319 A JP 2012535319A JP 2012535319 A JP2012535319 A JP 2012535319A JP 2013508382 A5 JP2013508382 A5 JP 2013508382A5
- Authority
- JP
- Japan
- Prior art keywords
- ethyl
- methyl
- pharmaceutically acceptable
- dihydropyrido
- tetrahydropyran
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 tetrahydropyran-4-yl Chemical group 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 2
- HONIICLYMWZJFZ-UHFFFAOYSA-N Azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000005017 Glioblastoma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Claims (3)
- 以下の式の化合物:
Aは
R1は、CH3、CH2CH3またはCF3であり;
R2は、H、CF3、CH2CF3、CH2CH2CF3、C1−C4アルキル、C3−C6シクロアルキル、CN、Cl、Br、CH=CH2、CH2CH2OCH3、C(CH3)2CH2OCH3またはテトラヒドロピラン−4−イルであり、ここでC3−C6シクロアルキルは1位においてメチルで任意に置換され、テトラヒドロピラン−4−イルは4位においてメチルで任意に置換され、R3はHであり;
またはR2およびR3は両方Clであり;
R4はHであり、R5はCH3、C(CH3)3、CH(CH3)2、シクロブチル、シクロペンチル、CH2−シクロプロピル、C(CH3)2CH2CH3またはテトラヒドロピラン−4−イルであり;
またはR4およびR5は両方CH3であり;
またはR4およびR5は、それらが結合するNと一緒に3位においてヒドロキシで任意に置換されるピロリジン、またはアゼチジンを形成する]
またはその医薬的に許容可能な塩。 - (R)−5−メチル−4−(4−(1−(2−(ピロリジン−1−イル)エチル)−4−(3,3,3−トリフルオロプロピル)−1H−イミダゾール−2−イル)ピペリジン−1−イル)−5,6−ジヒドロピリド[2,3−d]ピリミジン−7(8H)−オン;
(R)−4−(4−(4−エチル−1−(2−(ピロリジン−1−イル)エチル)−1H−イミダゾール−2−イル)ピペリジン−1−イル)−5−メチル−5,6−ジヒドロピリド[2,3−d]ピリミジン−7(8H)−オン;および
(R)−4−(4−(1−(2−(アゼチジン−1−イル)エチル)−4−(2,2,2−トリフルオロメチル)−1H−イミダゾール−2−イル)ピペリジン−1−イル)−5−(トリフルオロメチル)−5,6−ジヒドロピリド[2,3−d]ピリミジン−7(8H)−オン
から選択される請求項1に記載の化合物またはその医薬的に許容可能な塩。 - 請求項1または2に記載の化合物、またはその医薬的に許容可能な塩、および医薬的に許容可能な担体、希釈剤または賦形剤を含む、肺癌、乳癌または膠芽細胞腫を治療するための医薬製剤。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25430809P | 2009-10-23 | 2009-10-23 | |
US61/254,308 | 2009-10-23 | ||
PCT/US2010/053295 WO2011050016A1 (en) | 2009-10-23 | 2010-10-20 | Akt inhibitors |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2013508382A JP2013508382A (ja) | 2013-03-07 |
JP2013508382A5 true JP2013508382A5 (ja) | 2013-06-06 |
JP5581390B2 JP5581390B2 (ja) | 2014-08-27 |
Family
ID=43467018
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012535319A Expired - Fee Related JP5581390B2 (ja) | 2009-10-23 | 2010-10-20 | Akt阻害剤 |
Country Status (12)
Country | Link |
---|---|
US (1) | US8436002B2 (ja) |
EP (1) | EP2491032B1 (ja) |
JP (1) | JP5581390B2 (ja) |
KR (1) | KR101398268B1 (ja) |
CN (1) | CN102574852B (ja) |
AU (1) | AU2010310786B2 (ja) |
BR (1) | BR112012011328A2 (ja) |
CA (1) | CA2778291C (ja) |
EA (1) | EA020151B1 (ja) |
ES (1) | ES2465094T3 (ja) |
MX (1) | MX2012004780A (ja) |
WO (1) | WO2011050016A1 (ja) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA37647A1 (fr) | 2012-05-17 | 2016-03-31 | Genentech Inc | Procédé de fabrication de composés de cyclopentapyrimidine hydroxylée et sels de ceux-ci |
BR112014028593A2 (pt) | 2012-05-17 | 2017-12-19 | Genentech Inc | forma amorfa de um composto de pirimidinil-ciclopentano inibidor de akt, composições e métodos dos mesmos" |
CN104487430B (zh) | 2012-05-17 | 2016-08-24 | 阵列生物制药公司 | 用于制造羟基化的环戊基嘧啶化合物的方法 |
CA2873658C (en) | 2012-05-17 | 2021-01-26 | Genentech, Inc. | Process for making amino acid compounds |
CA2873654C (en) * | 2012-05-17 | 2021-06-22 | Array Biopharma Inc. | Process for making hydroxylated cyclopentylpyrimidine compounds |
EP2920154B1 (en) * | 2012-11-16 | 2017-10-11 | Merck Patent GmbH | Novel imidazol-piperidinyl derivatives as modulators of kinase activity |
SG10201900954SA (en) * | 2013-03-11 | 2019-02-27 | Merck Patent Gmbh | Heterocycles as Modulators of Kinase Activity |
WO2015013579A1 (en) | 2013-07-26 | 2015-01-29 | Update Pharma Inc. | Compositions to improve the therapeutic benefit of bisantrene |
US10526660B2 (en) | 2013-09-12 | 2020-01-07 | Dana-Farber Cancer Institute, Inc. | Methods for evaluating and treating Waldenstrom's macroglobulinemia |
GB201401198D0 (en) | 2014-01-24 | 2014-03-12 | Bial Portela & Ca Sa | Process for the syntheis of substituted urea compounds |
EP3110509B1 (en) | 2014-02-28 | 2020-08-19 | Merck Sharp & Dohme Corp. | Treating cancer with a combination comprising dinaciclib |
EP3459953B1 (en) * | 2016-05-20 | 2021-06-30 | Taiho Pharmaceutical Co., Ltd. | Novel 5h-pyrrolo[2,3-d]pyrimidin-6(7h)-one derivative |
EP3919491A4 (en) * | 2019-01-29 | 2022-10-19 | Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. | AKT INHIBITOR |
WO2021228223A1 (zh) * | 2020-05-15 | 2021-11-18 | 南京正大天晴制药有限公司 | 氘代akt激酶抑制剂 |
JP7499942B2 (ja) | 2020-07-22 | 2024-06-14 | 南京正大天晴制薬有限公司 | ジヒドロピリド[2,3-d]ピリミジノン誘導体の塩、その調製方法及び用途 |
US20230271958A1 (en) * | 2020-07-22 | 2023-08-31 | Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. | SALT AND CRYSTAL FORM OF DIHYDROPYRIDO[2,3-d]PYRIMIDINE DERIVATE |
CN115916350A (zh) * | 2020-07-22 | 2023-04-04 | 南京正大天晴制药有限公司 | Akt抑制剂的单位剂量组合物 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
US5362718A (en) | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
NL1004346C2 (nl) | 1996-10-23 | 1998-04-24 | Dsm Nv | Werkwijze voor het scheiden van een mengsel van enantiomeren in een geschikt oplosmiddel. |
KR100956195B1 (ko) | 2002-02-01 | 2010-05-06 | 어리어드 파마슈티칼스, 인코포레이티드 | 인 함유 화합물 및 이의 용도 |
US7563748B2 (en) | 2003-06-23 | 2009-07-21 | Cognis Ip Management Gmbh | Alcohol alkoxylate carriers for pesticide active ingredients |
US8076338B2 (en) | 2004-04-23 | 2011-12-13 | Exelixis, Inc. | Kinase modulators and methods of use |
WO2006000020A1 (en) | 2004-06-29 | 2006-01-05 | European Nickel Plc | Improved leaching of base metals |
MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
AU2005316668B2 (en) * | 2004-12-13 | 2012-09-06 | Millennium Pharmaceuticals, Inc. | Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors |
EP1848719B1 (en) | 2004-12-28 | 2012-02-01 | Exelixis, Inc. | [1h-pyrazolo[3,4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases |
CN101227857B (zh) | 2005-06-29 | 2011-10-19 | 电脑医师有限公司 | 具有导电桥的传感器组件 |
WO2007125325A1 (en) * | 2006-04-25 | 2007-11-08 | Astex Therapeutics Limited | Pharmaceutical compounds |
EP3421471B1 (en) | 2006-04-25 | 2021-05-26 | Astex Therapeutics Limited | Purine and deazapurine derivatives as pharmaceutical compounds |
TW200801513A (en) | 2006-06-29 | 2008-01-01 | Fermiscan Australia Pty Ltd | Improved process |
AR064416A1 (es) * | 2006-12-21 | 2009-04-01 | Cancer Rec Tech Ltd | Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas. |
UA99284C2 (ru) * | 2007-05-11 | 2012-08-10 | Елі Ліллі Енд Компані | ИНГИБИТОРЫ р70 S6-КИНАЗЫ |
AR074072A1 (es) * | 2008-11-11 | 2010-12-22 | Lilly Co Eli | Compuesto de imidazol -piperidin -pirrol-pirimidin-6-ona, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar el glioblastoma multiforme |
-
2010
- 2010-10-20 EP EP10774072.2A patent/EP2491032B1/en not_active Not-in-force
- 2010-10-20 CA CA2778291A patent/CA2778291C/en not_active Expired - Fee Related
- 2010-10-20 WO PCT/US2010/053295 patent/WO2011050016A1/en active Application Filing
- 2010-10-20 JP JP2012535319A patent/JP5581390B2/ja not_active Expired - Fee Related
- 2010-10-20 CN CN201080046941.9A patent/CN102574852B/zh not_active Expired - Fee Related
- 2010-10-20 US US13/391,895 patent/US8436002B2/en not_active Expired - Fee Related
- 2010-10-20 ES ES10774072.2T patent/ES2465094T3/es active Active
- 2010-10-20 AU AU2010310786A patent/AU2010310786B2/en not_active Ceased
- 2010-10-20 BR BR112012011328A patent/BR112012011328A2/pt not_active IP Right Cessation
- 2010-10-20 KR KR1020127010282A patent/KR101398268B1/ko not_active IP Right Cessation
- 2010-10-20 EA EA201270590A patent/EA020151B1/ru not_active IP Right Cessation
- 2010-10-20 MX MX2012004780A patent/MX2012004780A/es active IP Right Grant
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2013508382A5 (ja) | ||
AU2017260363B2 (en) | Modulators of the integrated stress pathway | |
JP2010540509A5 (ja) | ||
JP2019077725A5 (ja) | ||
HRP20171696T1 (hr) | 3,4-dihidroizokinolin-2(1h)-ilni spojevi | |
JP2009542613A5 (ja) | ||
JP2008513498A5 (ja) | ||
JP2013510124A5 (ja) | ||
JP2008535902A5 (ja) | ||
JP2006524660A5 (ja) | ||
JP2013510120A5 (ja) | ||
JP2011509309A5 (ja) | ||
JP2015529235A5 (ja) | ||
JP2009532452A5 (ja) | ||
JP2008525417A5 (ja) | ||
JP2011500758A5 (ja) | ||
JP2010241830A5 (ja) | ||
JP2016506962A5 (ja) | ||
JP2010523681A5 (ja) | ||
EP2620432A3 (en) | Diarylhydantoin compounds | |
JP2010515715A5 (ja) | ||
CN112041307B (zh) | 作为选择性雌激素受体降解剂的取代的苯并噻吩类似物 | |
JP2011507896A5 (ja) | ||
RU2017118165A (ru) | Ингибиторы энхансера гомолога 2 zestes | |
JP2015524450A5 (ja) |